Vertex Pharmaceuticals Inc
NASDAQ:VRTX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
392.81
516.74
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc
Unrealized Security Profit/Loss
Vertex Pharmaceuticals Inc
Unrealized Security Profit/Loss Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Unrealized Security Profit/Loss | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Unrealized Security Profit/Loss
$51.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
120%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Unrealized Security Profit/Loss
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Unrealized Security Profit/Loss
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Unrealized Security Profit/Loss
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Unrealized Security Profit/Loss
-$26.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Unrealized Security Profit/Loss
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
Glance View
In the bustling landscape of biotechnology, Vertex Pharmaceuticals Inc. stands out as a dynamic powerhouse that has deftly carved a niche in the complex domain of genetic therapies. Founded in 1989, the company initially embarked on a mission to revolutionize drug discovery through a cutting-edge rational drug design approach. Armed with an innovative spirit and a focus on niche markets, Vertex turned its attention towards cystic fibrosis—a life-shortening genetic disorder affecting the lungs and digestive system. The company’s breakthrough came with the development and approval of the first therapies that address the underlying cause of cystic fibrosis, rather than just alleviating symptoms. These products, including Kalydeco and Trikafta, have repositioned Vertex from a scrappy biotech upstart to a dominating force in the drug market as these life-changing treatments not only improve patient outcomes but also command premium pricing. Vertex’s business model brilliantly capitalizes on its deep investment in research and development, allowing it to maintain a robust pipeline that promises ongoing growth. By channeling a substantial portion of its revenue back into R&D, Vertex seeks to extend its therapeutic successes beyond cystic fibrosis into other serious diseases with high unmet needs, such as sickle cell disease and beta-thalassemia. This strategic reinvestment supports a cyclical framework of innovation—capitalize on current successes while laying down the groundwork for future therapies. With a singular focus on specialty drugs that target specific genetic mutations or pathways, Vertex not only thrives on the immediate financial returns of its blockbuster drugs but continually invests in scientifically ambitious endeavors, thus reinforcing its status as a leader in the precision medicine sector.
See Also
What is Vertex Pharmaceuticals Inc's Unrealized Security Profit/Loss?
Unrealized Security Profit/Loss
51.2m
USD
Based on the financial report for Sep 30, 2024, Vertex Pharmaceuticals Inc's Unrealized Security Profit/Loss amounts to 51.2m USD.
What is Vertex Pharmaceuticals Inc's Unrealized Security Profit/Loss growth rate?
Unrealized Security Profit/Loss CAGR 5Y
120%
You don't have any saved screeners yet
